A potent bispecific nanobody protects hACE2 mice against SARS-CoV-2 infection via intranasal administration.

ABSTRACT: The dramatically expanding coronavirus disease 2019 (COVID-19) needs multiple effective countermeasures. Neutralizing nanobodies (Nbs) are a potential therapeutic strategy for treating COVID-19. Here, we characterize several receptor binding domain (RBD)-specific Nbs isolated from an Nb library derived from an alpaca immunized with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike glycoprotein (S); among them, three Nbs exhibit picomolar potency against SARS-CoV-2 live virus, pseudotyped viruses, and circulating SARS-CoV-2 variants. To improve their efficacy, various configurations of Nbs are engineered. Nb₁₅-Nb_H-Nb₁₅, a trimer constituted of three Nbs, is constructed to be bispecific for human serum albumin (HSA) and RBD of SARS-CoV-2.

SUBMITTER: Wu X 

PROVIDER: S-EPMC8492916 | biostudies-literature | 2021 Oct

REPOSITORIES: biostudies-literature